A descriptive study to evaluate the effect of guidelines used by counsellors to improve adherence to antiretroviral therapy in the private sector by Marais, Melanie & Nikodem, Cheryl
JCHS Volume 1 No 2 October 2006 
A DESCRIPTIVE STUDY TO EVALUATE THE EFFECT OF GUIDELINES USED BY 
COUNSELLORS TO IMPROVE ADHERENCE TO ANTIRETROVIRAL THERAPY IN THE 
PRIVATE SECTOR 
Correspondence address: 
Prof. Dr. C. Nikodem 
Marais, Melanie (M Cur) 
School of Nursing, University of the Western Cape 
Nikodem, Cheryl, (DCur), Ass. Professor 
School of Nursing, University of the Western Cape 
School of Nursing, Universi ty of the Western Cape 
Private Bag x17, Bellville, 7535, South Africa 
Email. cnikodem@uwc.ac.za 
Abstract 
Introduction: To achieve a virological outcome to antiretroviral therapy, a high adherence level is required. 
Objective: To implement and evaluate guidelines that will be used by treatment support counsellors in an 
attempt to increase client adherence to antiretroviral treatment. 
Methods: A quasi - experimental comparative study was used to assess whether a structured treatment support 
guidelines can improve client adherence to antiretroviral therapy. The treatment outcome of two groups was 
compared: one group received the adherence guidelines and the other group was a historical group where no 
adherence guidelines were applied. The main outcome measure was whether adherence guidelines improved 
adherence to ART. 
Participants: Forty clients were exposed to the adherence guidelines and 34 were not. 
Setting: Clients that subscribe to Aids for Aids . 
Intervention: A structured guideline used by counsellors with regular contact. 
Results: Specific guidelines used by counsellors to improve adherence to antiretroviral therapy has shown that 
significantly more clients in the intervention group had their CD4 blood tests done after six months and adhered 
to regularly claim their medications. In addition were there more clients in the intervention group who had viral 
loads of less than 400 copies I ml after six months. 
Conclusion: Specific counselling using effective guidelines improve adherence to antiretroviral treatment. 
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Introduction 
The UNAIDS (2002:153) raised a general concern 
about extensive provision of antiretroviral therapy 
(ART) in all societies. A further concern is whether 
health systems have the capacity to ensure 
adherence to multifaceted ART regimens. There is 
a general consensus among researchers that an 
adherence level of 90 - 95% is required to achieve 
an acceptable virological outcome for most clients 
(Bartlett & Galant, 2002) Aids for Aids (AfA) points 
out that if adherence levels to ART's are below 80% 
an 80% reduction in the effect of ART could be 
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expected (AfA, 2005). AfA is a HIV I AIDS disease 
management company offering access to 
antiretroviral therapy (ART), prevention of 
opportunistic infections, treatment and blood results 
monitoring, treatment support through adherence 
coordinators and expert clinical support and advice 
to healthcare providers. They monitor treatment 
adherence through claims history, CD4 and viral 
load (VL) results as well as telephonic contact with 
the client. 
Rational 
AfA (2005) currently provides their employees as 
well as clients with information booklets pertaining 
to clinical guidelines in the management of human 
immune deficiency syndrome (HIV). These 
guidelines mainly concentrate on managing or 
treating the HIV-infected individual and not on the 
importance of adherence to ART. It appears from 
some client records that optimal viral suppression is 
not achieved, despite availability of these clinical 
guidelines. Failure to adherence of prescribed 
therapy is one of the main causes why optimal viral 
suppression may not be obtained. Clients are often 
advised by their healthcare providers to change 
their current therapy or to include other drugs. 
These changes of medication usually occur without 
investigation of their adherence to their current 
therapy regimen. A problem was identified at AfA 
whereby some doctors requested a change in 
treatment within less than a year after their patients 
started antiretroviral therapy. The requests were 
normally based on treatment failure. From the 
medication claim history, it was clear that the 
desired treatment outcome was not achieved due to 
poor adherence to therapy. The concern is that 
there are limited affordable drugs on the market and 
the danger of poor adherence and continuous 
changing of regimens is that it may result in an 
increase of mutations and viral resistance. Another 
problem that was identified was the fact that 
treatment support counsellors did not have a clearly 
formulated adherence guideline that could assist 
them to maintain a structured and consistent 
conversation with patients around the issue of 
adherence to ART. 
Objective 
The objective of this study was to determine the 
effectiveness of newly formulated adherence 
guidelines in antiretroviral treatment support to 
clients registered on the AfA disease management 
programme. 
Statement 
The authors postulated that clear adherence 
guidelines used by treatment support counsellors 
may enhance adherence to therapy and better 
adherence to therapy will result in less frequent 
change in treatment and enhance virology 
outcomes. 
Methods 
A quasi-experimental, descriptive study design was 
used to evaluate the effectiveness of the proposed 
adherence guideline. Thus there was no 
randomisation but a comparison group was used. 
The design for this study made use of an 
intervention and comparison group and the purpose 
of the design is quantitative-descriptive. 
Participants 
Two groups were selected for the purposes of this 
study. One group was identified as the intervention 
group (IG) and they were counselled by AFA 
counsellors who used structured adherence 
guidelines and were contacted at regular intervals. 
The control group (CG) were a historical group 
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where no structured adherence guidelines were 
used and where there were no control over the total 
number of contacts. The study population included 
all men and women over the age of 21 years who 
registered on the AfA program for the first time, had 
no previous experience of ART and qualified for 
Highly active antiretroviral treatment (HAART). The 
participants of the IG were selected from the overall 
population who registered on the AfA program from 
01 October 2004 until 30 November 2004. The 
participants in the CG were selected from the 
overall population who registered on the AfA 
program from 01 February 2004 until 31 March 
2004. All patients who qualified for the study had to 
either have a CD4 cell count of 250 cells I µL and 
less or had to qualify for ART based on an Aids 
defining illness. 
The records of medical scheme members, males 
and females over the age of 21 who were registered 
on the AfA programme were evaluated. Those who 
had previous exposure to ongoing ART and those 
who did not clinically qualify for therapy were 
excluded from the study. After applying the 
inclusion and exclusion criteria, the number of 
subjects in the intervention group (I G) was 40 and 
the number of subjects in the comparative group 
(CG) 34. 
Inclusion criteria 
The inclusion criteria included the following: 
• Men and women over the age of 21years; 
• Registered on the AfA program; 
• Started HAART for the first time within the 
period (months) as mentioned in the study 
population section; 
• Had to be members of a medical scheme 
administered by Medscheme to enable the 
researcher immediate access to their claims 
history. 
Exclusion criteria 
The exclusion criteria included the following: 
• All clients under the age of 21 years; 
• All medical schemes not administered by 
Medscheme at the time of the study period; 
• All corporate clients of AfA; 
• All medical schemes administered by external 
parties; 
• All international clients of AfA; 
• All the clients who received post exposure 
prophylaxis (PEP) at the time; 
• All clients with a CD4 cell count over 250 cells I 
µL who had no Aids defining illness; 
• All clients with a history of previous ART use. 
Setting: The study was conducted at AfA, a 
Medscheme Integrated Company. Members of 
medical schemes that are contracted with AfA may 
join the AfA programme when their HIV positive 
status is confirmed. 
Intervention 
Those in the IG were exposed to counsellors who 
used specific formulated guidelines and were 
contacted monthly for a period of six months. The 
CG consisted of client records which met the 
inclusion and exclusion criteria prior to the newly 
implemented guidelines. 
Research Instrument 
The research instrument (adherence guidelines) 
was administered to all subjects in the intervention 
group. The research instrument was a newly 
formulated adherence guideline that was applied at 
every contact with the subjects. This tool was 
formulated based on adherence literature as well as 
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inputs from AfA. The research instrument consisted 
of questions, advice to subjects and explanations to 
the treatment support counsellors to enable them to 
understand the context in which the questions were 
asked. Factors like self reporting (tolerability of 
ART, missed dosages), AfA adherence 
assessment, claims history, use of other medicines, 
problems experienced I adherence barriers, HIV 
status disclosure, reminders of follow up blood 
tests, emphasizing adherence to HAART, healthy 
lifestyle and intervention based on the interaction 
were included in the research instrument. The 
guidelines were administered in English and 
completed by 40 subjects. The content, face and 
construct validity of the instrument was evaluated. 
Data Analysis 
Data were analysed with Excel software and 
transferred from the excel spreadsheet using the 
SAS statistical package (SAS institute Inc., Cary, 
NC, USA). The data was cleaned and entered twice 
to ensure correctness. The first part of the data 
analysis gave descriptive statistics for each group 
separately. Tests of homogeneity of variance were 
applied to continuous variables. If the variables 
were homogenous, the ANOVA test was applied. If 
variables were heterogeneous, the Kruskal - Wallis 
Test was applied . The Chi - square test was used 
for proportion and the Fisher's exact test used when 
numbers were less than five. The results are 
expressed as means (standard deviation) or 
proportions. 
Ethical Approval 
The proposal of the study was submitted to the 
Senate Higher Degrees at the University of the 
Western Cape for ethical approval. Written consent 
was obtained from AfA to perform the study. Client 
confidentiality remained intact by keeping the 
collected data under an identification code (patient 
key number) and no form of identification of clients 
were added on to the thesis I published. 
Results 
All subjects were HIV - infected males and females 
over the age of 21 years who qualified for ART and 
registered on the AfA disease management 
programme. Forty subjects were exposed to the 
adherence guidelines and contacted on a monthly 
basis for six months. Their baseline variables and 
outcome variables were compared to the 34 
subjects (CG) that was not exposed to adherence 
guidelines. The two cohorts were similar with 
respect to age, gender, CD4 count, viral load and 
province. Baseline CD4 counts was available on all 
the subjects. Nearly all subjects 70 I 74 (94.5%) 
had a baseline CD4 of::: 250 cel ls I µI which met the 
ARV treatment inclusion criteria. Only four subjects 
had a baseline CD4 cell count of more than 250 
cells I µI, two in the IG (334 & 386 cells I µI) and two 
in the CG (256 & 267 cells I µI). The mean cells I µI 
were the same between the two groups 121.05 
(93.5) cells I µI IG and 121.47 (83.5) cells I µI CG, p 
= 0.983. Some subjects had cell counts of as little 
as 3 cells I µI and the ranges were IG (3.00 - 386 
cells I µI) and CG (5.00 - 267 cells I µI) (Table 1 ). 
All subjects in the IG had baseline viral loads done 
and the mean viral load for the IG was 156500.8 
(177491.2) copies I ml. One subject in the CG did 
not had a baseline viral load. The mean viral load in 
the CG was slightly higher 204 125.9 (244 467.1) 
but the difference was not significant, p = 0.412. 
Only 8 I 73 (10.9%) subjects had baseline viral 
loads of less than 100 000 copies I ml. It is 
recommended that viral load measures should 
rather be reported in Log10 because viral loads 
values may vary by up to three times, such as from 
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5000 - 15 000 and the variation appear to be large 
but this variation is within the margin of error of the 
test (AFA, 2005:9). The mean of the Log10 readings 
of the baseline viral load was similar IG 4.83 (626) 
Table 1 Biographical and baseline data 
with a range of 3.72 - 5.80 and CG 4.90 (747) with a 
range of 2.63 to 5.87 and a p value of 0.671 
Baseline variables Intervention group Control group P value 
N 40 N 34 
Age groups 25 - 56 26-48 0.164 
Gender (female) 31 /40 (77.5%) 24 / 34 (70.6%) 0.497 
Gender (male} 9 140 (22.5%) 10 / 34 (29.4%) 
Mean CD4 (cells/µ!) 121.05 (n 40) 121.47 (n 34) 0.983 
Mean Viral load (copies/ml) 156500.8 (n 40) 204 125.9 (n 33) 0.412. 
The majority of clients were from Kwazulu-Natal 
(KZN), (IG 19 vs CG 12). The same number of 
clients came from Gauteng, 8 in each group. Twelve 
clients were from the Free State (IG 3 vs CG 9) and 
eight were from the North West Province (IG 6 vs 
CG 2). The least subjects came from the Eastern 
Cape (IG 3 vs CG 2), Northern Cape (IG1 vs CG 0) 
and the Western Cape Province (IG 0 vs CG 1 ). 
It is important to note that no statistical differences 
were found in the baseline data between the 
intervention and the comparative groups. Thus the 
comparative group were comparable with the 
intervention group. 
7th Annual Congress of Midwives of South Africa 
10 to 14 December 2007 
Durban, South Africa 
Contact name: Robbie Cameron 
E-mail: robbie@rca.co.za (to e-mail the conference organizers) 
Organized by: The Society of Midwives of South Africa 
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Figure 1 Geographical distribution 
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Results 
The counsellors were able to contact the clients 
significantly more over the six month trial period (JG 
164 vs CG 35). The average calls per patient in the 
Intervention group were 4.7 vs. in the 
Comparative group. Significantly more clients in the 
intervention group returned for follow up CD4 blood 
counts (JG 37 vs CP 13). The mean CD4 count has 
improved in both groups. 
More clients had a viral load of less than 400 copies 
I ml after six months of treatment in the intervention 
group, but there were no statistical difference noted 
between the two groups (JG 28 /37 vs 7 I 13). 
Significantly more subjects in the intervention group 
claim their ART more regularly (JG 32/40 vs CG 
15/34). Fewer subjects in the intervention group 
WC EC FS NW 
Province 
changed treatment over the six month follow up 
time period (JG 4/40 vs CG 6/34). Side - effects 
such as a rash were the most common reason for 
changing therapy. As expected were there more 
side effects, more hospital visits and more hospital 
admissions in the intervention group. The reason 
for this is that the counsellors encourage clients to 
immediately seek medical advice when during the 
telephonic conversation it was detected that the 
client needs to see a medical practitioner. No 
deaths were recorded in the intervention group and 
two deaths were recorded in the comparison group 
(Table 2). 
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Table 2 Outcome Variables 
Outcome variables Intervention Group Comparative Group p value 
N 40 34 
Contacts 164 35 0.000 
Follow up CD4 blood test 37 I 40 (92.5%) 13 I 34 (38.2%) 0.001 
Mean CD4 229.2 (n37) 263.5 (n13) 0.824 
CD4 range (cells I µI) 45-568 (n37) 53- 1000 (n13) 0.824 
Viral load < 400 copies I ml 28 I 37 (76%) 7 I 13 (54%) 0.152 
ART claims 32 I 40 (80%) 15 I 34 (44%) 0.003 
Change in treatment 4 I 40 (10%) 6 I 34 (17.6%) 0.497 
Side effects 10 I 39 (25.6%) 5 I 34 (14.7%) 0.388 
Mean doctor visits 5.3 (n40) 5.1 (n34) 0.455 
Hospital admissions 13 I 40 (32.5%) 6 I 34 (17.6%), 0.480 
Deaths 0 2 0.400 
Discussion Fear of discrimination cause people not to 
More females enrolled on the AfA programme. 
Interestingly, both female groups in this study 
presented with a 70.5 to 77.5% females, which is 
more or less in line with the Khayelitsha HIV I AIDS 
pilot where 70% women accessed ART. The 
Khayelitsha HIV I AIDS pilot proved that there is a 
clear improvement in mortality rate compared to 
people not on ART. They found that the survival 
rate is higher among women. Men were 1.89 times 
more likely to die. They also had poor adherence 
and follow ups over a period of 18 months. Support 
systems and counselling services are not 
sufficiently supportive for men and there are more 
female caregivers who do not encourage men to 
participate in these programmes (De Pinho, 2003: 
6). Studies have shown that gender has an impact 
on access to health care services and adherence to 
treatment. There was no significant difference in 
the gender distribution between our study. 
participate in programmes like VCT to get to know 
their status. Some people get tested late in the 
disease where they already present with AIDS 
defining illnesses. This could be explained why 
some of the subjects in the two groups had baseline 
CD4 cell counts below 200 cells I µI. 
It is evident in literature that adherence to ART 
reduces VL to undetectable levels and increases 
CD4 cell counts. We can therefore make the 
assumption that those subjects in the CG, that did 
not claim their treatment, were non - adherent and 
would therefore, not have had undetectable VL and 
an increase in CD4 cell counts. The high 
adherence level to follow up blood tests in the IG 
was a very important outcome that clearly proved 
that the designed adherence intervention made a 
huge impact not only to follow up blood tests but 
also to the clinical outcome of these tests. 
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Side - effects have been reported as one of the 
reasons why some clients decide to discontinue 
their treatment (Brannon & Feist, 1992:262; 
Andrews, 2002:19). It is possible that in some 
cases, the side - effects caused the subjects in the 
CG to either discontinue their treatment or claim 
their treatment irregularly. If this assumption is 
correct, then poor adherence could probably have 
been avoided if these subjects were contacted 
regularly. The subjects in the IG were informed 
about possible side - effects, how to manage side -
effects and encouraged to continue treatment. 
Studies have shown that patient self - reporting is 
not a reliable measure of adherence (Brannon & 
Feist, 1992:257 - 258). It is possible that some of 
the subjects were not completely honest with their 
doctors about their adherence to ART. Doctors' 
estimation of their client's adherence is reported to 
be unreliable. Friedland reported that doctors' 
measurement of their client's adherence is less 
accurate than their clients' self - reports. Studies 
have shown a difference of 45% in client self -
reporting and doctors' reporting of their clients' 
adherence to treatment (Friedland, 2002:36; USA 
collaborative group, [sa]). According to Brannon 
and Feist (1992:257), although patient self - report 
is more accurate than that of their physicians, they 
may lie or be uncertain about their adherence to 
therapy. The claim history was therefore used in 
this study to assess adherence and significantly 
more clients in the intervention group submitted 
their claims. 
Implications for practice 
All counsellors should use specific guidelines when 
they contact clients. Clients should be contacted on 
a regular basis at least once per month to increase 
adherence to ARV therapy. 
Conclusion 
In summary, the impact of HIV I AIDS and its 
treatment highlighted the importance of the need to 
have an effective disease management programme 
in place. It has also brought about the emphasis for 
health care workers to have counselling skills in 
place. People living with HIV I AIDS have a need to 
be empowered with knowledge about their disease 
and its impact in order to make informed decisions 
about their health and their future in the midst of 
myths and mixed messages. Poor adherence to a 
treatment regimen has remained a huge a problem 
throughout the world and effective management is 
needed to improve adherence to treatment. Not 
only should patients be educated about their 
disease but also encouraged towards behaviour 
change that would enhance their health status. In 
order to reach this goal, the commitment of the 
patient and health care providers are required and 
patients encouraged involving family, friends and 
the community for social support. 
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